Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 27;14:699–710. doi: 10.2147/OTT.S284211

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Expression of CPNE1 was enhanced in CRC tissues. (A) CPNE1 mRNA in tumor and normal tissues from CRC patients.**p < 0.01 vs normal. (B) IHC assay of CPNE1 protein levels in CRC tissue arrays including adjacent normal tissues (n=5) and CRC tissues (n = 105). *p < 0.05 vs para-cancerous, ***p < 0.001 vs para-cancerous. Correlation analyses between CPNE1 expression and survival of CRC patients. (C and D) mRNA level of CPNE1 from TCGA dataset (CRC: n = 638; healthy control: n = 51) and GEO dataset with accession number GSE33113 (CRC: n = 90, healthy control= 6). **p < 0.01 vs normal. (E) Kaplan–Meier survival curves showing the difference of survival time between patients with low and high expression of CPNE1 on CRC samples from 105 patients. ***p < 0.001.